Relay Therapeutics, Inc. (RLAY) recently announced that it had achieved positive interim data from its ongoing phase 1 ReDiscover study, using its drug RLY-2608 + fulvestrant for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results